Table 1.
Characteristics of patients who had ≥50% programmed cell death-1 ligand-1 positivity
| Characteristics | Total n = 49 |
ATA-negative n = 36 |
ATA-positive n = 13 |
p value |
| Age (years) | 69 ± 10 | 70 ± 8 | 69 ± 11 | 0.781 |
| <70 | 22 | 16 | 6 | 1.000 |
| ≥70 | 27 | 20 | 7 | |
| Sex | ||||
| Female | 13 | 6 | 7 | 0.024 |
| Male | 36 | 30 | 6 | |
| BMI (kg/m2) | 21 ± 3 | 21 ± 3 | 21 ± 4 | 0.451 |
| <25 | 43 | 31 | 12 | 1.000 |
| ≥25 | 6 | 5 | 1 | |
| Drugs | ||||
| Nivolumab | 2 | 1 | 1 | 0.464 |
| Pembrolizumab | 47 | 35 | 12 | |
| Tumor histology | ||||
| SCC | 12 | 8 | 4 | 0.708 |
| Non-SCC | 37 | 28 | 9 | |
| ECOG PS | ||||
| <2 | 46 | 34 | 12 | 1.000 |
| ≥2 | 3 | 2 | 1 | |
| Brain metastases | ||||
| Yes | 5 | 5 | 0 | 0.306 |
| No | 44 | 31 | 13 | |
| Liver metastases | ||||
| Yes | 7 | 4 | 3 | 0.363 |
| No | 42 | 32 | 10 | |
| Bone metastases | ||||
| Yes | 14 | 12 | 2 | 0.297 |
| No | 35 | 24 | 11 | |
| Smoking history | ||||
| Current/former | 39 | 30 | 9 | 0.422 |
| Never | 10 | 6 | 4 |
Data are represented by the mean ± SD or n.
ATA: anti-thyroid antibody
BMI: body mass index
SCC: squamous cell carcinoma
Non-SCC: non-squamous cell carcinoma
ECOG PS: Eastern Cooperative Oncology Group performance status